WALTHAM, Mass. – Syndax Prescription drugs (NASDAQ: NASDAQ:), a medical stage biopharmaceutical firm, has reported encouraging outcomes from trials of revumenib, its acute leukemia drug candidate. On the European Hematology Affiliation 2024 Congress in Madrid, findings from two trials, BEAT AML and AUGMENT-102, had been introduced, showcasing the drug’s potential together with different therapies for treating acute myeloid leukemia (AML).
Within the BEAT AML trial, revumenib was examined alongside venetoclax/azacitidine in sufferers over 60 with newly recognized mutant nucleophosmin (mNPM1) or KMT2A-rearranged (KMT2Ar) AML. A powerful 96% composite full remission charge was noticed, with 92% of sufferers reaching minimal residual illness (MRD) damaging standing. The trial additionally reported a 100% estimated 12-month survival charge for the primary cohort.
The AUGMENT-102 trial targeted on a predominantly pediatric inhabitants with relapsed/refractory (R/R) mNPM1, NUP98-rearranged (NUP98r), or KMT2Ar AML. It mixed revumenib with fludarabine/cytarabine, leading to a 52% composite full remission charge. Moreover, 71% of sufferers who achieved CRc and had evaluable knowledge reached MRD damaging standing, with a number of continuing to hematopoietic stem cell transplant.
Security profiles from each trials counsel that revumenib might be administered successfully with out rising the frequency or severity of adversarial occasions, even in closely pretreated sufferers. The outcomes assist the continued growth of revumenib as a possible remedy choice throughout varied acute leukemia settings.
Syndax is making ready for the anticipated near-term approval of revumenib within the relapsed or refractory setting and plans to provoke a pivotal trial with the BEAT AML mixture by the top of 2024. The corporate can also be advancing revumenib as a monotherapy, with its dose at the moment below FDA assessment.
These research are a part of Syndax’s broader efforts to develop revolutionary most cancers therapies.
The information introduced on the EHA Congress relies on a press release assertion from Syndax Prescription drugs.
In different latest information, Pyxis Oncology and Syndax Prescription drugs introduced vital additions to their respective boards. Pyxis Oncology appointed Michael A. Metzger, a biopharma trade veteran and present CEO of Syndax Prescription drugs. Metzger’s appointment comes as Pyxis continues to advance its antibody-drug conjugates and immuno-oncology applications.
In the meantime, Syndax Prescription drugs welcomed Aleksandra Rizo, M.D., Ph.D., to its board. Dr. Rizo’s intensive expertise in hematology medicine is anticipated to contribute considerably to Syndax’s strategic transition to a commercial-stage group.
When it comes to monetary efficiency, Syndax Prescription drugs outlined a strong Q1 2024 efficiency throughout its latest earnings name. The corporate reported a robust money place of $522 million, anticipated to final by means of 2026.
Analysts have been intently monitoring Syndax’s progress. The corporate has been persistently rated “Overweight” by analysts, together with Barclays Capital Inc. and JPMorgan. Regardless of damaging earnings per share forecasts, the analysts preserve a optimistic outlook on Syndax’s trade as a consequence of its promising drug pipeline and strategic monetary administration.
Within the realm of biotechnology, Syndax Prescription drugs has emerged as a notable participant, particularly with its pioneering work on revumenib, a Menin inhibitor, which has been displaying vital potential within the remedy of assorted cancers. The corporate’s drug pipeline is powerful, with two vital PDUFA dates on the horizon, doubtlessly resulting in market approval.
InvestingPro Insights
As Syndax Prescription drugs (NASDAQ: SNDX) continues to make strides within the growth of its acute leukemia drug candidate, revumenib, the monetary well being and market notion of the corporate stay crucial for buyers. With a give attention to the corporate’s newest efficiency and future outlook, listed here are some key insights primarily based on real-time knowledge from InvestingPro and InvestingPro Suggestions:
InvestingPro knowledge highlights a market capitalization of $1.76 billion for Syndax, reflecting the market’s valuation of the corporate’s potential. Regardless of the challenges confronted in profitability, with a damaging P/E ratio of -6.38 and an adjusted P/E ratio for the final twelve months as of Q1 2024 at -7.31, the corporate’s strategic strikes in advancing revumenib may very well be a game-changer. Moreover, the corporate’s price to e-book ratio stands at 3.58, suggesting that buyers are prepared to pay a premium for what they consider to be a strong pipeline with vital future progress potential.
From the attitude of InvestingPro Suggestions, Syndax holds more money than debt on its steadiness sheet, which is a optimistic signal for monetary stability and future investments in research and growth. Furthermore, 8 analysts have revised their earnings upwards for the upcoming interval, indicating a optimistic sentiment in direction of the corporate’s monetary prospects. That is notably related as Syndax prepares for pivotal trials and seeks FDA approval for revumenib. Nevertheless, it is value noting that analysts don’t anticipate the corporate can be worthwhile this yr, and web earnings is anticipated to drop. This data may very well be essential for buyers contemplating the long-term worth and the dangers related to the corporate’s progress trajectory.
For these concerned with a deeper dive into Syndax’s financials and future projections, there are extra InvestingPro Suggestions accessible, which might be accessed by visiting https://www.investing.com/professional/SNDX. To boost your research expertise, use the coupon code PRONEWS24 to get an extra 10% off a yearly or biyearly Professional and Professional+ subscription. With quite a few ideas at your disposal, you can also make extra knowledgeable funding choices relating to Syndax Prescription drugs.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.